Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California. Show more

1300 Rancho Conejo Boulevard, Thousand Oaks, CA, 91320, United States

Biotechnology

Healthcare

Market Cap

1.528B

52 Wk Range

$17.22 - $25.93

Previous Close

$23.04

Open

$23.25

Volume

90,472

Day Range

$22.21 - $24.40

Enterprise Value

1.384B

Cash

42.18M

Avg Qtr Burn

-27.07M

Insider Ownership

4.98%

Institutional Own.

75.30%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LTG-321 Details Osteoarthritis pain	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onzotrigine (formerly LTG-001) Details Moderate-to-severe acute postoperative pain following bunionectomy	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.